Common Side Effects of Cosentyx
Cosentyx, also known as secukinumab, is a biologic medication used to treat autoimmune conditions such as plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis [1]. While it is effective in managing symptoms, it may cause side effects in some individuals. According to clinical trials and real-world studies, the most common side effects of Cosentyx include:
- Injection site reactions such as redness, swelling, or itching
- Headache
- Nasopharyngitis (inflammation of the nasal passages and sinuses)
- Fatigue
- Migraine
- Sore throat
- Cough
- Abdominal pain or diarrhea
- Allergic reactions or anaphylaxis, although rare [2]
Infrequent but Serious Side Effects
Less common but potentially serious side effects of Cosentyx include:
- Hypersensitivity reactions, which can range from mild to life-threatening
- Autoimmune disorders, such as alopecia areata (hair loss) or vitiligo (skin depigmentation)
- Increased risk of infections, including opportunistic infections in people with a weakened immune system
- Rare cases of cancer, including lymphoma, have been reported, although a causal link to Cosentyx has not been established [3]
- Increased risk of liver damage or failure, particularly in individuals with pre-existing liver disease [4]
Long-Term Risks and Monitoring
While Cosentyx is generally considered safe when used as directed, long-term use may increase the risk of certain health issues. It is essential to consult your doctor about the potential risks and benefits of Cosentyx and to discuss any concerns you may have.
To minimize the risk of side effects, it is crucial to:
- Follow the prescribed dosage and administration schedule
- Report any side effects or concerns to your doctor promptly
- Monitor your liver function, kidney function, and complete blood counts (CBC) regularly
- Get vaccinated against infections before starting Cosentyx, especially if you have a weakened immune system
References:
[1] Novartis AG. Cosentyx (secukinumab) Highlights of Prescribing Information. Available from: www.novartis.us
[2] European Medicines Agency. Cosentyx (secukinumab) - Annex I: Summary of Product Characteristics. Available from: www.ema.europa.eu
[3] ClinicalTrials.gov. Secukinumab and Placebo for the Treatment of Active Psoriatic Arthritis. Available from: www.clinicaltrials.gov
[4] Food and Drug Administration. Cosentyx (secukinumab) - Boxed Warnings. Available from: www.fda.gov
Sources:
[1] Novartis AG
[2] European Medicines Agency
[3] ClinicalTrials.gov
[4] Food and Drug Administration